Ein neuer Stern am Himmel Zecotek Medical - 500 Beiträge pro Seite
eröffnet am 09.11.06 08:26:37 von
neuester Beitrag 09.11.06 08:33:50 von
neuester Beitrag 09.11.06 08:33:50 von
Beiträge: 3
ID: 1.093.172
ID: 1.093.172
Aufrufe heute: 0
Gesamt: 462
Gesamt: 462
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 34 Minuten | 7253 | |
| vor 33 Minuten | 6499 | |
| heute 21:02 | 4924 | |
| vor 1 Stunde | 4738 | |
| vor 29 Minuten | 4336 | |
| heute 19:35 | 2745 | |
| vor 1 Stunde | 2500 | |
| vor 47 Minuten | 2207 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.179,00 | +1,33 | 219 | |||
| 2. | 2. | 156,89 | +10,45 | 135 | |||
| 3. | 19. | 0,1910 | +4,95 | 81 | |||
| 4. | 3. | 2.322,19 | -0,19 | 61 | |||
| 5. | 43. | 0,0262 | +63,75 | 49 | |||
| 6. | 9. | 43,75 | -3,42 | 45 | |||
| 7. | 17. | 4,7480 | +3,15 | 43 | |||
| 8. | 30. | 14,475 | +5,46 | 41 |
Feedback
Press Release Source: Zecotek Medical Systems
Zecotek Granted U.S. Patent for LFS Scintillation Material
Wednesday November 8, 6:00 am ET
VANCOUVER, British Columbia, Nov. 8, 2006 (PRIMEZONE) -- Zecotek Medical Systems Inc. (TSX VENTURE:ZMS.V - News) (Frankfurt:W1I.F - News) today announced the official issuance of a U.S. patent for its LFS scintillation material. The U.S. patent number is 7,132,060.
ADVERTISEMENT
``This represents a critical step for Zecotek to achieve market acceptance. This will particularly provide the PET and PET-CT manufacturers the required assurance to adopt the LFS crystal as an alternative high performance and cost effective scintillation material for their high resolution scanners. The granting of the LFS patent is a significant technical validation that will also offer Northrop Grumman, the Company\'s manufacturing and distribution alliance, an added technical validity to proceed confidently with the manufacturing and the World-wide sale of the LFS and its unique derivatives, under the assurance of a U.S. patent,\'\' stated Dr. Faouzi Zerrouk, Chairman and CEO.
About the Company
Zecotek Medical Systems Inc. is a market driven, Canadian research and development bio-photonics company. The Company is focused on the creation of advanced materials and integrated optoelectronic devices for high-resolution medical imaging, optical precision surgery, biopharmaceutical research, and 3D displays. The Company commercializes its technologies directly as well as through strategic alliances with leading OEM manufacturers and distributors. Zecotek\'s R&D facility in Singapore will create alliances and share in intellectual properties in a unique and growing industry. Shares of Zecotek are listed for trading on the TSX Venture Exchange under the symbol ``ZMS.\'\'
For additional information on Zecotek Medical Systems and our technologies please see our Website at http://www.zecotekmed.com
The Zecotek Medical Systems company logo is available at http://www.primezone.com/newsroom/prs/?pkgid=3001
Contact:
Zecotek Medical Systems Inc.
Michael Minder, CFO; VP Corporate Development
(604) 689-4200 x3
mminder@zecotek.com
CHF Investor Relations
Jan C. Moir, Vice President
(416) 868-1079 x237
jan@chfir.com
--------------------------------------------------------------------------------
Source: Zecotek Medical Systems
Zecotek Granted U.S. Patent for LFS Scintillation Material
Wednesday November 8, 6:00 am ET
VANCOUVER, British Columbia, Nov. 8, 2006 (PRIMEZONE) -- Zecotek Medical Systems Inc. (TSX VENTURE:ZMS.V - News) (Frankfurt:W1I.F - News) today announced the official issuance of a U.S. patent for its LFS scintillation material. The U.S. patent number is 7,132,060.
ADVERTISEMENT
``This represents a critical step for Zecotek to achieve market acceptance. This will particularly provide the PET and PET-CT manufacturers the required assurance to adopt the LFS crystal as an alternative high performance and cost effective scintillation material for their high resolution scanners. The granting of the LFS patent is a significant technical validation that will also offer Northrop Grumman, the Company\'s manufacturing and distribution alliance, an added technical validity to proceed confidently with the manufacturing and the World-wide sale of the LFS and its unique derivatives, under the assurance of a U.S. patent,\'\' stated Dr. Faouzi Zerrouk, Chairman and CEO.
About the Company
Zecotek Medical Systems Inc. is a market driven, Canadian research and development bio-photonics company. The Company is focused on the creation of advanced materials and integrated optoelectronic devices for high-resolution medical imaging, optical precision surgery, biopharmaceutical research, and 3D displays. The Company commercializes its technologies directly as well as through strategic alliances with leading OEM manufacturers and distributors. Zecotek\'s R&D facility in Singapore will create alliances and share in intellectual properties in a unique and growing industry. Shares of Zecotek are listed for trading on the TSX Venture Exchange under the symbol ``ZMS.\'\'
For additional information on Zecotek Medical Systems and our technologies please see our Website at http://www.zecotekmed.com
The Zecotek Medical Systems company logo is available at http://www.primezone.com/newsroom/prs/?pkgid=3001
Contact:
Zecotek Medical Systems Inc.
Michael Minder, CFO; VP Corporate Development
(604) 689-4200 x3
mminder@zecotek.com
CHF Investor Relations
Jan C. Moir, Vice President
(416) 868-1079 x237
jan@chfir.com
--------------------------------------------------------------------------------
Source: Zecotek Medical Systems
Whnsinn ein 20 Jähriges Patent hier wirds bald Kurse geben wo andere davon Träumen.
Meiner Meinung nach ein klarer Kauf.
Antwort auf Beitrag Nr.: 25.233.620 von Mick1968 am 09.11.06 08:28:01du glaubs auch alles. dann schau dir mal enpar an.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 210 | ||
| 92 | ||
| 91 | ||
| 63 | ||
| 49 | ||
| 48 | ||
| 40 | ||
| 36 | ||
| 33 | ||
| 30 |
| Wertpapier | Beiträge | |
|---|---|---|
| 28 | ||
| 23 | ||
| 23 | ||
| 21 | ||
| 21 | ||
| 20 | ||
| 20 | ||
| 19 | ||
| 18 | ||
| 18 |
